FDA clears CytoDyn mid-stage leronlimab trial for mild-to-moderate COVID-19

CytoDyn (OTCQB:CYDY) announces that the FDA has provided clearance for initiation of a Phase 2 trial with leronlimab to treat COVID-19 patients with mild-to-moderate indications.

The Company’s IND, leronlimab, has been administered to 10 severely ill patients with COVID-19 in the New York City area under an emergency IND recently granted by the FDA.

The Phase 2 trial calls for 75 planned patients in up to 10 centers in the U.S. The treatment window is of approx. 6 weeks.

https://seekingalpha.com/news/3556648-fda-clears-cytodyn-s-mid-stage-leronlimab-trial-for-mild-to-moderately-ill-covidminus-19